The L-DOPA-sparing effect of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in reserpine-pretreated rats

Life Sciences

Volumn 72, Issue 12, 2003, Pages 1413-1419

  Shimazu, Seiichiro ^a   Tamashiro, Akiko ^a   Yoneda, Fumio ^a   Knoll, Joseph ^b  

^a Fujimoto Pharmaceutical Corporation   (Japan)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Catecholaminergic and serotonergic activity enhancer; L DOPA; L DOPA sparing; Parkinson's disease; R ( ) 1 (Benzofuran 2 yl) 2 propylaminopentane hydrochloride ( ) BPAP ; Reserpine

Indexed keywords

1 (BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; BENZOFURAN DERIVATIVE; LEVODOPA; RESERPINE; UNCLASSIFIED DRUG;

ARTICLE; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; MALE; NONHUMAN; RAT; SEROTONIN RELEASE;

ALPHA-METHYLTYROSINE; ANIMALS; BENZOFURANS; DRUG SYNERGISM; LEVODOPA; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RESERPINE;

EID: 0037422934     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02411-6     Document Type: Article

References (20)

1. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B.H. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1(8009):1977;439-443.
2. Effect of deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine. 321(20):1989;1364-1371.
3. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 245(4917):1989;519-522.
4. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacology and Toxicology. 82(2):1998;57-66.
5. Knoll J., Miklya I. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication. Life Sciences. 56(8):1995;611-620.
6. Knoll J., Miklya I., Knoll B., Markó R., Kelemen K. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sciences. 58(10):1996;817-827.
7. Knoll J., Knoll B., Miklya I. High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Life Sciences. 58(11):1996;945-952.
8. Knoll J., Miklya I., Knoll B., Markó R., Rácz D. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sciences. 58(23):1996;2101-2114.
9. Knoll J. Memories of my 45 years in research. Pharmacology and Toxicology. 75(2):1994;65-72.
10. Knoll J., Yoneda F., Knoll B., Ohde H., Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. British Journal of Pharmacology. 128(8):1999;1723-1732.
11. Knoll J. Antiaging compounds: (-)deprenyl (selegiline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. CNS Drug Reviews. 7(3):2001;317-345.
12. Yoneda F., Moto T., Sakae M., Ohde H., Knoll B., Miklya I., Knoll J. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorganic and Medicinal Chemistry. 9(5):2001;1197-1212.
13. Shimazu S., Takahata K., Katsuki H., Tsunekawa H., Tanigawa A., Yoneda F., Knoll J., Akaike A. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. European Journal of Pharmacology. 421(3):2001;181-189.
14. Hamabe W., Fujita R., Yasusa T., Yoneda F., Yoshida A., Ueda H. (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors. Cellular and Molecular Neurobiology. 20(6):2000;695-702.
15. Carlsson A. Monoamine-depleting drugs. Pharmacology and Therapeutics. 1(3):1975;393-400.
16. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology. 26(9):1987;1431-1440.
17. Betarbet R., Sherer T.B., Greenamye J.T. Animal models of Parkinson's disease. Bioessays. 24(4):2002;308-318.
18. + channel in the guinea-pig substantia nigra. Exp. Brain Res. 110(3):1996;360-366.
19. Mignon L., Wolf W.A. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl.). 163(1):2002;85-94.
20. Brocco M., Dekeyne A., Veiga S., Girardon S., Millan M.J. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol. Biochem. Behav. 71(4):2002;667-680.